Punjab: Now, get free dengue tests at Aam Aadmi Clinics
'Dengue (NSI ELISA) testing has been initiated at all the Aam Aadmi Clinics (AACs) across Punjab through the public-private partnership (PPP) mode in collaboration with Path Care Labs,' reads the letter issued by Punjab health department director.
Private labs charge anywhere between ₹1,000– ₹1,500 for the dengue tests.
Before this decision, ELISA-based dengue tests were conducted at only district and civil hospitals. Consequently, patients were compelled to visit private labs for dengue testing.
In the wake of intermittent rain over the past few days, health officials were on alert. They said that the prevailing weather conditions were conducive to dengue breeding. The state has already reported over 100 cases this season.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Dr Reddy's Q1 result: Net profit up 2%, revenue hits record ₹8,545 crore
Hyderabad-based pharma major Dr Reddy's Laboratories (DRL) posted a consolidated net profit of ₹1,417 crore in the first quarter of financial year 2026 (Q1 FY26), a 2 per cent rise from ₹1,392 crore a year ago. The company clocked its highest-ever quarterly revenue at ₹8,545 crore, up 11 per cent year-on-year (Y-o-Y) from ₹7,672 crore. The increase in profit and revenue was attributed to new product launches and price hikes during the quarter. Sequentially, revenue was flat, with a marginal 0.4 per cent rise, while net profit declined by 11 per cent. G V Prasad, co-chairman and managing director, DRL, said: 'We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio.' Dr Reddy's is planning a major global rollout of semaglutide beginning in 2026, targeting 87 countries—including India, Brazil, Canada, and Turkey—subject to local patent expiries. In countries without active patents, launches will begin earlier. In India and Brazil, where the patent expires in March 2026, the company is targeting Day 1 launches. Erez Israeli, chief executive officer, DRL, said: 'The semaglutide launch is very important to us. It reflects our focus on business development, resource optimisation, and cost alignment for future growth. While there are execution risks, I'm confident we'll overcome them and continue our growth trajectory. Our pipeline includes 26 peptide-based GLP-1 products, expected to launch over the next decade.' Despite ongoing litigation with Novo Nordisk in India regarding the validity of the semaglutide patent, Dr Reddy's does not anticipate any delays or disruptions to its commercialisation plans. The company expects significant topline contribution from semaglutide, citing growing global demand for GLP-1 therapies in diabetes and weight management. Priced lower than Novo's offering (₹17,000 per month), Dr Reddy's plans to use its integrated manufacturing to enhance accessibility. Semaglutide is the first of 26 GLP-1 peptide-based drugs the company plans to launch globally over the next decade, with timing based on regional IP clearance. Dr Reddy's has guided for capital expenditure of approximately ₹2,700 crore in FY26, with major investments toward expanding peptide and biosimilar capacity in line with product-specific requirements. Segment Performance Global Generics: Revenue stood at ₹8,060 crore, up 10 per cent Y-o-Y, supported by new launches and stable volumes. North America: Revenue was ₹3,412 crore, down 11 per cent Y-o-Y due to price erosion in key products like Lenalidomide. The company launched five new products and filed one ANDA with the USFDA. As of June 2025, 73 filings are pending, including 70 ANDAs (43 Para IVs, 22 with potential First-to-File status) and three NDAs. Europe: Revenue surged 142 per cent Y-o-Y to ₹1,274 crore, driven by the NRT acquisition. The NRT business contributed ₹670 crore. Germany reported ₹320 crore (up 13 per cent), the UK ₹170 crore (up 10 per cent), and the rest of Europe ₹120 crore (up 30 per cent). Growth was led by new launches and forex gains, partly offset by price erosion. Thirteen new products were launched. Emerging Markets: Revenue rose 18 per cent Y-o-Y to ₹1,404 crore. Russia contributed ₹710 crore (up 28 per cent), the Commonwealth of Independent States and Romania ₹200 crore (up 2 per cent), and the rest of world territories ₹500 crore (up 13 per cent). A total of 26 new products were launched across these regions. Pharmaceutical Services and Active Ingredients: Revenue rose 7 per cent Y-o-Y to ₹818 crore, supported by new API launches, forex gains, and pharmaceutical services expansion. The company filed 12 Drug Master Files globally during the quarter. The results were announced post market hours. Dr Reddy's shares rose 0.58 per cent, closing at ₹1,247.50 apiece on the BSE.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Natco Pharma to acquire 35.75% stake in Adcock Ingram for ₹2,000 cr
The proposed Rs 2,000 crore deal will give Natco Pharma a strategic foothold in South Africa, with transaction completion expected within four months subject to approvals Sanket Koul New Delhi In a bid to enter the African market, Natco Pharma on Wednesday announced that it has submitted a firm intention for a ZAR 4 billion (Rs 2,000 crore) cash offer to acquire a minority stake in South Africa-based drugmaker Adcock Ingram Holdings (AIHL). If approved, the Hyderabad-based company will hold a 35.75 per cent stake in Adcock Ingram by offering ZAR 75.00 ($4.271) per share to minority stakeholders. The deal gives Natco a gateway into South Africa, with AIHL holding a 10 per cent share of the private pharmaceutical market in the country. It is also the largest supplier of hospital and critical care products in South Africa. This transaction would consolidate Natco's existing 0.80 per cent stake, making it the second-largest shareholder in AIHL, behind the Bidvest Group, which holds the remaining 64.25 per cent. 'Post-transaction, Natco will consolidate 35.75 per cent of AIHL's net profits in Natco's financial results in accordance with its shareholding,' the company said in a regulatory filing. If the deal proceeds, Adcock Ingram will be delisted from the Johannesburg Stock Exchange (JSE) and will continue to operate as a private South African business. Rajeev Nannapaneni, chief executive officer and vice-chairman of Natco Pharma, said the proposed acquisition would help the company tap into new revenue streams and expand its presence in one of the largest and fastest-growing emerging markets. In return, AIHL is expected to leverage Natco's research and development capabilities, regulatory expertise, and global marketing network to support local leadership and expansion into new markets. 'AIHL will benefit from a partnership with a research-focused, innovative, and vertically integrated pharmaceutical company, and over time, South Africans will be beneficiaries of wider access to affordable medicines,' said Andrew Hall, chief executive officer, AIHL. Valued at an estimated ZAR 11 billion ($632 million), AIHL generated revenues of ZAR 9.6 billion ($536 million) for the financial year ending June 2024. Founded in 1890, the company operates across four segments—prescription, consumer, over-the-counter (OTC), and hospitals. It has a diverse product portfolio ranging from generic and branded formulations to critical-care hospital products, as well as consumer and home-care products. The announcement was made after market hours. On Wednesday, Natco Pharma's shares rose by 2.01 per cent, ending the day's trade at Rs 1,034.75 apiece on the Bombay Stock Exchange (BSE).
Hans India
4 hours ago
- Hans India
Dr. Reddy's Laboratories' net profit slumps 11 pc to Rs 14,09 crore sequentially in Q1
Mumbai: Dr. Reddy's Laboratories' net profit stood at Rs 1,409.6 crore in the first quarter of the current fiscal (Q1 FY26), down 11 per cent sequentially, the company said in an exchange filing on Wednesday. The company had reported a consolidated profit of Rs 1,587.3 crore in the preceding quarter (Q4 FY25). However, the profit of the Hyderabad-based firm saw a marginal jump of over a per cent on year-on-year (YoY) from Rs 1,392 crore in the same quarter a year ago, according to the filing. Meanwhile, Dr. Reddy's Labs revenue stood at Rs 8,545.2 crore in the quarter under review, up around Rs 40 crore sequentially from Rs 8,506 crore, and Rs 872.5 crore year-on-year (YoY) from Rs 7,672.7 crore. The pharmaceutical company saw a jump of Rs 153 crore in its total operating expenses this quarter QoQ, leading to a decline in its net profit. The company reported total operating expenses of Rs 3,115.2 crore in Q1 FY26 against Rs 2,961.6 crore in Q4 FY25. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market," said GV Prasad, Co-Chairman and MD. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad added. Meanwhile, the company has expanded partnership with Alvotech to co-develop, manufacture and co-commercialise pembrolizumab, a biosimilar candidate, this quarter, as per the filing. It has also launched Sensimune in India, an immunotherapy product for house dust mite-induced allergies. The shares of the company closed in positive territory on Wednesday. The stock settled at Rs 1,248.0, up 0.65 per cent. Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad.
